Tags : Based

Top 20

Top 20 Generics Pharma Companies Based On 2019 Revenue

The global generics pharmaceutical market has become an intimidating segment of the pharmaceutical drug market which continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs. Generics are approved copies of small molecule drugs that contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, […]Read More

Biotech

Roche Expands its Collaboration with Immunomedics to Evaluate Tecentriq Based

Shots: The companies extend their existing collaboration to evaluate Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) in combination with Tecentriq (atezolizumab) in patients with mUC and mNSCLC. The partners have ongoing collaboration in 1L metastatic triple-negative BC Roche will conduct two P-Ib/II studies utilizing MORPHEUS platform. The MORPHEUS-mUC study will evaluate Tecentriq + Trodelvy vs Tecentriq as monothx. […]Read More

Regulatory

Pfizer with its Partner BioNTech Receives the US FDA’s Fast

Shots: The designation is based on preliminary data from P-I/II study assessing BNT162b1 including animal immunogenicity studies results that were released on Jul 01, 2020. Additionally, the early results of German trial evaluating BNT162b1 are expected in Jul 2020 The companies BNT162 mRNA-based vaccine program involves the evaluation of 4 investigational candidates developed to target […]Read More

Biosimilars Clinical Trials

Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in

Shots: Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg, day 1-21, qd) + acalabrutinib (100mg, day 1-28, bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma In the 13 patients who underwent disease assessment following the R2A regimen, ORR (69%) and CR (31%), […]Read More

Top 20

Top 20 Biopharma Acquisitions of 2018 Based on the Total

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 […]Read More

Top 20

Top 20 Diagnostics Companies Based On 2018 Revenue

With the era of growing diseases, Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing, with a greater focus on value, reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at […]Read More